Although MM treatment has improved, patients with disease refractory to multiple standard-of-care drug classes face a dismal prognosis. Melflufen demonstrated efficacy and tolerability in select populations, with an initial approval in the United States in patients with ≥ four previous lines of therapy and triple-class-refractory MM. Results from the phase III OCEAN study - currently under discussion with regulatory agencies in the United States and Europe - are more complex and have been put into context herein. Lastly, melflufen provides a proof-of-concept for the utility of the peptide-drug conjugate platform in relapsed/refractory MM.
Meletios A Dimopoulos, Fredrik Schjesvold, María‐Victoria Mateos, Paweł Robak, Roman Hájek, Paul G. Richardson, Jakob Lindberg, Marcus Thuresson, Kajsa Larsson, Pieter Sonneveld
Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Stefan Norin, Marcus Thuresson, A. Bergan, Jakob Obermüller, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld
Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff, Farzana L. Walcott, Nabendu Pore, Miranda Brown, Fujun Wang, Lily Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yuling Wu, Yu Jiang, Robert Kubiak, Jeffrey A. Zonder, Jeremy T. Larsen, Shreerang Sirdesai, Andrew J. Yee, Shaji Kumar
Pieter Sonneveld, Paul G. Richardson, Heinz Ludwig, Meletios A Dimopoulos, Fredrik Schjesvold, Roman Hájek, Haifaa Abdulhaq, Marcus Thuresson, Stefan Norin, Nicolaas A. Bakker, María‐Victoria Mateos
Paul G. Richardson, Jacob P. Laubach, Sagar Lonial, Philippe Moreau, Sung‐Soo Yoon, Vânia TM Hungria, Meletios A Dimopoulos, Meral Beksaç, Melissa Alsina, Jesús F. San Miguel
Discussion(0)
No comments yet. Be the first to comment.